Pfizer, Inc. · NYSE:PFE
Pfizer — Investor Day (December 2021)
17 slides from Pfizer's investor day presentation, Dec 13, 2021
Slide 1: Inflammation & Immunology Investor Day
Inflammation & Immunology Investor Day December 13, 2021 Breakthroughs that change patients’ lives Confidential 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and our discussions during this conference call will include forward-looking statements and forward-looking information that are subject to substantial risks and uncertainties, many of which are beyond our control, that could cause actual results to diffe
Slide 3: Today's Speakers
Today’s Speakers Aamir Malik Mike Gladstone Mike Corbo Mike Vincent EVP, Chief Business I&I Global President I&I Chief Development Officer I&I Chief Scientific Officer Innovation Officer Confidential 3 3
Slide 4: Capital allocation priorities
Capital allocation priorities Maintain discipline in deciding where to put our R&D investments to generate the Advance most return internal pipeline Find creative options to increase our speed, manage risk, and make the most impact on patient health Seek compelling Pursue compelling later-stag
Slide 5: Capital allocation priorities
Capital allocation priorities Maintain discipline in deciding where to put our R&D investments to generate the Advance most return internal pipeline Find creative options to increase our speed, manage risk, and make the most impact on patient health Seek compelling Pursue compelling later-stag
Slide 6: The Need is Great. The Future is Bright.
The Need is Great. The Future is Bright. Patients’ Unmet Medical Needs Drive Pfizer’s Commitment and Investment in Immuno-Inflammatory Diseases Rheumatology Gastroenterology Medical Dermatology Heterogeneity of patient population in immuno-inflammatory diseases requires a pipeline with multiple comp
Slide 7: Announcing Agreement to Acquire Arena Pharmaceuticals
Announcing Agreement to Acquire Arena Pharmaceuticals: An exciting opportunity to offer patients new potential therapies and diversify our Pfizer portfolio Strategic Value to Pfizer and Potential Near-Term options for IBD Patients Anticipated Strong portfolio fit Differentiated MOA revenue and capab
Slide 8: Pfizer's Expertise in Commercialization Brings Potential Therapies to Patients Sooner
Pfizer’s Expertise in Commercialization Brings Potential Therapies to Patients Sooner Deep R&D Expertise Global Supply Chain Excellence Commercial Infrastructure Robust footprint in immuno- Manufacturing operational excellence Existing commercial infrastructure to inflammation science with access to
Slide 9: Etrasimod: A Selective S1P1, S1P4, and S1P5 Receptor Modulator
Etrasimod: A Selective S1P1, S1P4, and S1P5 Receptor Modulator Etrasimod is a novel oral, selective sphingosine 1- Why Etrasimod is Potentially Best-In-Class Agent phosphate (S1P) receptor modulator in development for immuno-inflammatory diseases Differentiated Etrasimod is a potent agonist of the S
Slide 10: Etrasimod: Phase 2 Efficacy in Ulcerative Colitis (UC)
Etrasimod: Phase 2 Efficacy in Ulcerative Colitis (UC) UC Efficacy Overview Etrasimod vs. Ozanimod in UC • Randomized placebo-controlled, dose-ranging, Phase 2 study (OASIS) evaluated the efficacy and safety of etrasimod in moderate-to-severe UC patients over 12 weeks • Cross trial comparison showed
Slide 11: Etrasimod Provides Pipeline Diversification and Significant Potential Revenue Contribution
Etrasimod Provides Pipeline Diversification and Significant Potential Revenue Contribution in Critical 2025-2030 Timeframe Expands Pfizer’s current offering in IBD Best-in-Class efficacy potential in Ulcerative Colitis, and robust risk-benefit profile Potential Lifecycle expansion into Crohn's
Slide 12: Pfizer Offers Robust Differentiated Pipeline of Immuno-Inflammation Potential Therapies
Pfizer Offers Robust Differentiated Pipeline of Immuno-Inflammation Potential Therapies Currently Marketed Products Investigational Assets Rheumatology ADALIMUMAB-AFZB Adalimumab biosimilar Rheumatoid Arthritis; a-IFNβ Lupus; Dermatomyositis; Psoriatic Arthritis and Ankylosing Spondylitis IRAK4/Ritl
Slide 13: Pfizer Pipeline Highlights: TL1A and Anti-IFNβ
Pfizer Pipeline Highlights: TL1A and Anti-IFNβ TL1A: A monoclonal antibody for IBD with Anti-Interferon β: A monoclonal antibody potential for precision medicine with first-in-class potential for dermatomyositis and more SCIENCE • TL1A amplifies cytokine production and • IFN-β protein levels elevate
Slide 14: Pfizer's Differentiated Immuno-Inflammatory Pipeline and Portfolio Brings Potential Value
Pfizer’s Differentiated Immuno-Inflammatory Pipeline and Portfolio Brings Potential Value to Patients and Shareholders Serving Patients Strong Strategic Fit Value to Shareholders • Pfizer is committed to the patients • Pfizer capabilities aligned to Etrasimod • Proposed acquisition aligns with our w
Slide 15: Thank You
Thank You Breakthroughs that change patients’ lives Confidential 15
Slide 16: Back-up Slides
Back-up Slides Breakthroughs that change patients’ lives Confidential 16
Slide 17: Arena Pipeline Overview
Arena Pipeline Overview Asset (MoA) / Indication Pre-Clinic Phase 1 Phase 2 Phase 3 Etrasimod (S1P) • Ulcerative Colitis • Crohn’s Disease • Atopic Dermatitis • Alopecia Areata • Eosinophilic Esophagitis 1 Other Pipeline and Partnered Assets • Ralinepag (IP agonist) / PAH • RIST4721 (CXCR2) / PPP •